Because the expression of GPR68 and ARNTL in monocytes in patients with CKD correlates with renal function [10], targeting these molecules in monocytes/macrophages could offer potential therapeutic strategies for treating CKD-induced cardiovascular disorders. Here, BMAL1 is linked to chronic kidney disease.